Bharat biotech commences clinical trials of Spanish tuberculosis vaccine in India

Subject: Science and tech

Section: Health

Why in news?

Bharat Biotech will conduct phase 3 of the trial to evaluate the safety and immunogenicity of the Spanish TB vaccine (MTBVAC)

More about MTBVAC:

MTBVAC is the only vaccine undergoing clinical trial based on the genetically modified form of mycobacterium tuberculosis, a pathogen that causes disease
The new vaccine contains all the antigens in the present strains that infect human
MTBVAC vaccine promised to be a more effective and potentially longer-lasting vaccine than the BCG vaccine
Promise vaccine for newborns, adults, and adolescents for whom there is currently no effective vaccine

About BCG vaccine:

BCG vaccine is an attenuated variant of bovine TB pathogen and more than a 1oo year old so have limited effect on pulmonary tuberculosis that responsible for the transmission of the disease